AICAR Dosage, Reconstitution & Mixing Trends

Explore aicar calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized aicar calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What AICAR Is

AICAR is a small-molecule AMPK activator (a nucleotide analogue) studied in metabolic and exercise-physiology research. It is a chemical compound, not a peptide, so the certificate of analysis (COA) is about chemical purity and identity rather than a sequence.

AICAR is taken up by cells and phosphorylated to ZMP, which mimics AMP and allosterically activates AMP-activated protein kinase (AMPK) — the master cellular energy sensor that responds to falling ATP and rising AMP by switching cells from anabolic to catabolic metabolism.[3] AMPK activation triggers downstream effects that include increased fatty-acid oxidation, glucose uptake, mitochondrial biogenesis (via PGC-1α), and inhibition of mTOR-driven anabolic signalling. The Narkar 2008 paper attributed the endurance phenotype in mice to AMPK-driven reprogramming of skeletal muscle toward oxidative fibre type.[1]

AICAR was originally developed as a cardioprotective and anti-leukemic drug (acadesine) and reached Phase 3 in chronic lymphocytic leukemia (the BENDA-Acadesine program), where it did not advance.[4] Its post-2008 prominence is almost entirely driven by the exercise-mimetic claim and its WADA-prohibited status.[1][2] No registered human trial has tested AICAR for chronic exercise-mimetic use or healthspan extension, and the human pharmacokinetics published from the cardiology era show very short plasma half-life requiring continuous infusion.[5]

Not FDA-approved. Investigated historically as acadesine for cardioprotection and CLL (discontinued). On the WADA Prohibited List (S4 hormone and metabolic modulators) since 2009. Research-grade material for non-clinical use; no chronic-use human safety data exists.

AICAR Research Sources

AICAR Dosing Context

AICAR has a reported half-life of ~1 hour. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. Cleared within a couple of hours, so there is essentially no buildup between daily doses. The effect is driven by each individual dose. Pharmacokinetic source: Acadesine (AICA riboside) clinical cardiac-surgery pharmacokinetic studies. It is catalogued under Performance Peptides on WPA.

AICAR Community Calculator Data

39 AICAR reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

AICAR Research Background and Calculator Data

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) is a small-molecule purine analog that is converted intracellularly to ZMP, an AMP-mimetic that binds and activates AMPK (AMP-activated protein kinase) — the central cellular energy sensor that drives the metabolic shift to fatty acid oxidation, mitochondrial biogenesis, and glucose uptake when ATP availability falls. Pharmacological AMPK activation through AICAR drives the same downstream transcriptional programs as endurance exercise, which is the mechanistic basis for AICAR's reputation as an "exercise mimetic". The pivotal experimental result is the Narkar et al. paper in Cell (2008) from the Ronald Evans laboratory at the Salk Institute, in which sedentary mice treated with AICAR (or with the PPAR-delta agonist GW501516) showed substantially improved running endurance versus untreated controls — demonstrating, for the first time at scale, that pharmacological substitution for endurance training was achievable in a rodent model. The Salk work directly motivated the World Anti-Doping Agency (WADA) decision to add AICAR to the Prohibited List as a metabolic modulator, and the molecule has been associated with several high-profile doping cases in endurance sport since. The clinical record in humans is much thinner: small studies in cardiac surgery (myocardial protection) and metabolic disease have explored AICAR pharmacology, but no AICAR-based therapy has reached approval in any market, and human pharmacokinetics and safety at the doses suggested by the rodent endurance work remain only partially characterized.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.